Response to Comment on Mizokami-Stout et al. The Contemporary Prevalence of Diabetic Neuropathy in Type 1 Diabetes: Findings From the T1D Exchange. Diabetes Care 2020;43:806–812 | Zendy

Kara MizokamiStout | Zendy; Zoey Li | Zendy; Nicole C. Foster | Zendy; Lynn Ang | Zendy; Rodica PopBusui | Zendy

Open Access

Response to Comment on Mizokami-Stout et al. The Contemporary Prevalence of Diabetic Neuropathy in Type 1 Diabetes: Findings From the T1D Exchange. Diabetes Care 2020;43:806–812

Author(s) -

Kara MizokamiStout,

Zoey Li,

Nicole C. Foster,

Lynn Ang,

Rodica PopBusui

Publication year - 2020

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dci20-0028

Subject(s) - medicine , diabetes mellitus , hypertriglyceridemia , peripheral neuropathy , diabetic retinopathy , odds ratio , type 2 diabetes , diabetic neuropathy , retinopathy , physical therapy , pediatrics , endocrinology , triglyceride , cholesterol

We thank Professor Kostev for his comments (1) on our manuscript that evaluated the contemporary prevalence of diabetic peripheral neuropathy (DPN) in 5,936 participants with type 1 diabetes (T1D) in the T1D Exchange Clinic Registry (2). As described, we found a DPN prevalence of 11% as defined by the Michigan Neuropathy Screening Instrument Questionnaire (MNSIQ) (2). Our study highlighted several nonglycemic risks factors including hypertriglyceridemia (odds ratio [OR] 1.03, 95% CI 1.01, 1.05) and smoking (OR 1.83, 95% CI 1.18, 2.82) and other complications including retinopathy (OR 1.46, 95% CI 1.14, 1.88) and cardiovascular disease (CVD) (OR 1.73, 95% CI 1.24, 2.42) (2).We elected to use the MNSIQ because it is a simple, noninvasive measure of DPN that has …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research